Stryker Co. (NYSE:SYK) Shares Sold by Marshall Wace North America L.P.

Marshall Wace North America L.P. reduced its stake in shares of Stryker Co. (NYSE:SYK) by 97.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,494 shares of the medical technology company’s stock after selling 90,602 shares during the quarter. Marshall Wace North America L.P.’s holdings in Stryker were worth $492,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. ERTS Wealth Advisors LLC acquired a new position in Stryker in the 4th quarter valued at $25,000. Farmers National Bank acquired a new stake in shares of Stryker in the 1st quarter worth $25,000. Semmax Financial Advisors Inc. acquired a new stake in shares of Stryker in the 4th quarter worth $28,000. Truehand Inc acquired a new stake in shares of Stryker in the 4th quarter worth $30,000. Finally, Cable Hill Partners LLC acquired a new stake in shares of Stryker in the 1st quarter worth $30,000. 73.57% of the stock is owned by hedge funds and other institutional investors.

In other Stryker news, insider Timothy J. Scannell sold 4,666 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $186.71, for a total transaction of $871,188.86. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Glenn S. Boehnlein sold 2,700 shares of the business’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $188.21, for a total value of $508,167.00. Following the sale, the chief financial officer now owns 23,333 shares in the company, valued at $4,391,503.93. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,377 shares of company stock worth $4,144,870. Company insiders own 7.20% of the company’s stock.

A number of analysts have issued reports on the company. Wells Fargo & Co reaffirmed a “hold” rating on shares of Perrigo in a research note on Tuesday, July 2nd. ValuEngine upgraded Yirendai from a “strong sell” rating to a “sell” rating in a report on Friday, May 3rd. Morgan Stanley lowered their price target on Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating for the company in a report on Tuesday. Deutsche Bank increased their price target on Texas Instruments from $100.00 to $110.00 and gave the stock a “hold” rating in a report on Wednesday, April 24th. Finally, Canaccord Genuity set a C$16.50 target price on Detour Gold and gave the company a “buy” rating in a report on Wednesday, April 24th. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $202.46.

SYK traded up $2.50 during trading on Thursday, hitting $210.45. 866,416 shares of the stock were exchanged, compared to its average volume of 1,261,214. The company’s fifty day simple moving average is $200.13. Stryker Co. has a 1-year low of $144.75 and a 1-year high of $210.85. The company has a market cap of $77.59 billion, a price-to-earnings ratio of 28.79, a P/E/G ratio of 2.49 and a beta of 0.87. The company has a quick ratio of 1.30, a current ratio of 2.12 and a debt-to-equity ratio of 0.68.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, April 23rd. The medical technology company reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.84 by $0.04. Stryker had a return on equity of 26.72% and a net margin of 25.38%. The company had revenue of $3.52 billion for the quarter, compared to the consensus estimate of $3.51 billion. During the same period last year, the business posted $1.68 EPS. The company’s revenue was up 8.5% on a year-over-year basis. On average, analysts forecast that Stryker Co. will post 8.15 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be paid a $0.52 dividend. The ex-dividend date is Thursday, June 27th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 0.99%. Stryker’s dividend payout ratio (DPR) is presently 28.45%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: What does a bar chart display?

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.